Hormone replacement therapy (HRT) use among women in the United States has nearly doubled since January 2017 [1].
This trend reflects a shift in how menopausal symptoms are managed across the country. Because menopause affects more than one million women each year in the U.S. [2], changes in treatment adoption can have significant implications for public health and pharmaceutical demand.
Reports said that the use of these therapies has seen approximately a 100% increase between January 2017 and April 2026 [1]. The growth suggests a changing perception of the risks and benefits associated with hormone treatments for menopausal women.
However, some data presents a more complex picture of the current landscape. A study based at the Mayo Clinic said that hormone therapy use among women in the U.S. remains low, even though it is considered an effective treatment [2]. This creates a contradiction between the reported doubling of use and the overall low penetration of the therapy in the general population.
Medical professionals continue to evaluate the long-term efficacy of these treatments. The disparity in reporting suggests that while the rate of adoption is increasing rapidly, a large portion of the eligible population still does not utilize HRT for symptom management [1], [2].
“Hormone replacement therapy (HRT) use among women in the United States has nearly doubled since January 2017”
The conflicting data suggests a 'growth from a small base' phenomenon. While a 100% increase indicates a significant shift in patient behavior or physician prescribing habits over the last nine years, the overall usage rate may still be low relative to the millions of women experiencing menopause annually. This gap highlights a potential disconnect between the clinical effectiveness of HRT and its actual adoption in the U.S. healthcare system.
